TSE •
Healthcare •
Biotechnology •
Quote as of 08/26/2026 15:30
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTSE
Market Capitalization8,672.59 mln
Float18.15 mln
Earnings Date08/12/2025
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.45
Reliable
Relative Strength
99
/ 100
Top performer
Debt / Equity
-13.45
Negative equity
ROE
-123
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Founded in Kobe, Japan in 2003, Carna Biosciences is a clinical-stage drug development company focused on addressing serious diseases that currently lack effective treatments. The company supplies specialized proteins and laboratory testing services to support drug discovery research worldwide. Its most advanced pipeline candidates are three oral medicines targeting cancers such as leukemia and solid tumors, as well as inflammatory and immune conditions, each working by blocking specific proteins that drive disease progression.
